TVARDI THERAPEUTICS, INC.

Tvardi Therapeutics Tvardi Therapeutics names Imran Alibhai Chief Executive Officer Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Imran Alibhai, Ph.D. as Chief Executive Officer and a member of the Board of Directors, effective immediately. “After a competitive national search, we are delighted to welcome Dr. Alibhai to Tvardi,” said Ron […] The post Tvardi Therapeutics names Imran Alibhai Chief Executive Officer first appeared on Tvardi Therapeutics and is written by JoeNewTV

Tvardi Therapeutics Former M.D. Anderson president’s new Houston company names first CEO Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, named Imran Alibhai as its CEO, effective immediately. Alibhai most recently served as a senior vice president and managing director of Houston-based DNAtrix Inc., a clinical-stage biopharmaceutical company developing oncolytic viruses for cancer, […] The post Former M.D. Anderson president’s new Houston company names first CEO first appeared on Tvardi Therapeutics and is written by JoeNewTV

Tvardi Therapeutics Tvardi Therapeutics Names Imran Alibhai Chief Executive Officer Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Imran Alibhai, Ph.D. as Chief Executive Officer and a member of the Board of Directors, effective immediately. “After a competitive national search, we are delighted to welcome Dr. Alibhai to Tvardi,” said Ron […] The post Tvardi Therapeutics Names Imran Alibhai Chief Executive Officer first appeared on Tvardi Therapeutics and is written by JoeNewTV

Tvardi Therapeutics Tvardi’s Scientific Advisory Board Member, Dr. Jim Allison, Wins Nobel Tvardi is pleased to announce that Jim Allison, Scientific Advisory Board Member of the company, has just won the Nobel Prize.  The Nobel Prize in physiology or medicine was awarded Monday morning, October 1, 2018, to cancer researchers James P. Allison and Tasuku Honjo whose studies led to the development of drugs that unleash the […] The post Tvardi’s Scientific Advisory Board Member, Dr. Jim Allison, Wins Nobel first appeared on Tvardi Therapeutics and is written by JoeNewTV

Tvardi Therapeutics Tvardi Announces Series A Financing Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round. Series A funding is expected to enable the completion of ongoing Phase 1 studies for Tvardi’s lead compound TTI-101 in solid tumor cancers, and the completion of […] The post Tvardi Announces Series A Financing first appeared on Tvardi Therapeutics and is written by JoeNewTV

Tvardi Therapeutics Former M.D. Anderson president’s new Houston company secures funding, seeks CEO Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, secured $9 million in a Series A financing round. Tvardi develops a cancer drug that acts as an inhibitor to STAT3 — a signaling molecule that, when left unrestrained, can sometimes lead to […] The post Former M.D. Anderson president’s new Houston company secures funding, seeks CEO first appeared on Tvardi Therapeutics and is written by JoeNewTV